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Type 1 Gaucher disease (GD) is the most common lysosomal storage disorder. 
Previously, treatment for GD was limited to intravenous enzyme replacement therapy (ERT). 
ERT reduces symptoms and increases health­related quality of life (HRQoL) in people with this 
condition. In 2014, oral substrate reduction therapy (SRT) was approved for type 1 GD 
treatment. Although both therapies alleviate disease symptoms, effects of SRT on HRQoL and 
preferences for therapy are not well established. Electronic surveys were administered to adults 
with type 1 GD. HRQoL was scored with the Short Form­36 Version 2​®​ Health Survey and 
descriptive statistics were used to evaluate additional survey items. No differences in physical 
HRQoL (​p ​= 0.756) or mental HRQoL (​p​ = 0.650) were observed between SRT and ERT users. 
SRT users most often perceived their health to be similar to when they used ERT. Additionally, 
SRT users expressed convenience and non­invasiveness as reasons for choosing SRT, while 
many ERT users cited potential side effects and satisfaction with ERT as reasons for declining 
SRT. There appears to be no difference in HRQoL between ERT and SRT users and no 
perceived change in HRQoL for SRT users that previously used ERT. Participant responses 
illustrate that one particular treatment may not be ideal for all patients with type 1 GD depending 
on perceived convenience, invasiveness, or side effects. This evidence suggests that individuals 
with type 1 GD be adequately counseled about the risks and benefits of both therapy options now 
that SRT is clinically available.  
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1 
INTRODUCTION 
 
Lysosomal storage diseases (LSDs) are a group of genetic disorders that affect the ability 
of lysosomes to break down waste inside of various cells of the body. There are approximately 
50 different types of LSDs that are clinically recognized and the most common of these is 
Gaucher Disease (GD) [Grabowski, 1993]. GD involves a deficiency of the enzyme 
glucocerebrosidase and, as a result, impedes the ability of lysosomes to break down a 
glycosphingolipid called glucosylceramide that can accumulate within the cells of organs such as 
the spleen, liver, kidneys, brain, lungs, and bone marrow [Beutler, 1991]. 
 GD is most common in Ashkenazi Jewish populations and, depending on the mutation 
and phenotypic classification, individuals with GD can be broken down into three different types 
[Azuri et al, 1998; Koprivica et al, 2000]. Type 1 GD is the most common form of the disease 
and is often referred to as non-neuropathic due to the fact that there are no neurological 
symptoms of the disease in these patients. Types 2 and 3 are considered acute and chronic 
neuropathic forms of the disease, respectively, and can result in neurologic symptoms such as 
seizures or movement disorders [Beutler, 1991; Grabowski, 1993]. Symptoms that can be present 
in all three types of GD include hepatosplenomegaly, anemia, bone and joint pain, and lung 
disease [Beutler, 1991]. 
 While there is no cure for GD, enzyme replacement therapies (ERTs) were introduced to 
the medical community in 1991 as a treatment for non-neurologic symptoms of GD. Therefore, 
these courses of treatment have been most effective for treatment in patients with type 1 GD 
[Kay et al, 1991; Verderese et al, 1993]. ERT must be given through infusion biweekly over the 
course of several hours and many individuals use central venous access devices (CVADs) for 
therapy administration. In August, 2014, a new treatment referred to as substrate reduction 
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therapy (SRT) was approved by the Food and Drug Administration (FDA) for patients with type 
1 GD [Futerman et al, 2004]. This type of therapy is delivered orally once or twice daily 
depending on patient metabolizer status and has been proven to be as effective as ERT in 
treatment of physical symptoms of the disease throughout its clinical trial [Kamath et al, 2014; 
Lukina et al, 2014; Poole, 2014; Mistry et al, 2015]. 
 Although SRT is effective at treating physical manifestations of type 1 GD, little is 
known regarding the influence this novel therapy could have on the health related quality of life 
(HRQoL) of individuals with this genetic condition. In the past, HRQoL has been used to collect 
information about the physical and psychosocial effects of chronic disease on patients’ lives. 
Patients with chronic conditions such as fibromyalgia, chronic obstructive pulmonary disease 
(COPD), and acquired immunodeficiency syndrome (AIDS) have lower HRQoL than members 
of the general population across several different categories including physical and mental 
quality of life [Schlenk et al, 1998]. While studies of chronic genetic disorders have historically 
focused on identification and treatment of manifestations, learning about HRQoL for patients 
with certain genetic conditions may allow health care providers, such as medical geneticists and 
genetic counselors, to better understand the disease burden of these individuals and the impact 
that their disease has on everyday life [Sprangers & Aaronson, 1992]. Previous studies have 
shown that patients with type 1 GD, as well as other LSDs such as Fabry disease and Pompe 
disease, have a decreased HRQoL when compared with United States population norms 
[Damiano et al, 1998; Hayes et al, 1998; Masek et al, 1999; Gold et al, 2002; Giraldo et al, 2005; 
Kanters et al, 2011; Bouwman et al, 2011]. Furthermore, ERT has been shown to improve 
HRQoL in patients with type 1 GD [Damiano et al, 1998; Masek et al, 1999; Weinreb et al, 
2007]. 
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Due to the recent availability of SRT for patients with type 1 GD, no study to date has 
captured the perception of disease burden and HRQoL in patients that are specifically utilizing 
SRT for treatment. Because SRT is an oral therapy, it may impact patients differently, while still 
providing the same symptom relief for GD. As a result, HRQoL in patients with type 1 GD using 
SRT may be different than what is reported in the literature for patients using ERT. Additionally, 
patients who used ERT in the past but who are currently using SRT may report a self-perceived 
increase in some aspects of quality of life. In this study, we sought to investigate whether or not 
patients using SRT to treat non-neuropathic GD have similar or better HRQoL and perception of 
disease burden than those patients using ERT. This information could be instrumental in 
educating healthcare providers and patients about the full range of risks and benefits of these 
courses of treatments outside of treating the physical manifestations of the disease. 
 
MATERIALS AND METHODS 
Participants and Data Collection 
 
A link to a study questionnaire was posted in online group forums consisting of patients 
with type 1 GD and their family members, including the Yahoo! Gaucher Disease group 
(https://groups.yahoo.com/neo/groups/gaucherdisease/info), the National Gaucher Foundation 
(NGF) website (http://www.gaucherdisease.org/), and the National Gaucher Foundation of 
Canada (NGF Canada) listserv. Additionally, letters describing the study purpose were sent 
electronically to physicians at GD treatment centers, as well as to genetic counselors that belong 
to the Metabolic Special Interest Group within the National Society of Genetic Counselors. 
These healthcare providers were provided with study access information so that their interested 
patients could participate in this research. Electronic advertisements were sent every three weeks 
to the online groups and healthcare providers during a collection period ranging from October 
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12th, 2015 to January 7th, 2016. To be eligible to participate in this study, individuals had to be 
18 years of age or older and have a self-reported diagnosis of type 1 GD. Participants were 
informed prior to beginning the survey that two dollars would be donated to the NGF for each 
complete survey that was submitted. Participants were also asked to identify if they had 
participated in this study previously so that responses would not be duplicated. The total number 
of individuals with type 1 GD that this survey reached is unknown due to a paucity of data on the 
number of patients approached by the healthcare providers and the degree of overlap between 
patient populations and support groups; therefore, a response rate could not be reliably 
determined. Research data was collected through REDCap™, a secure electronic survey portal. 
Informed consent was obtained as a precursor for individuals to begin the survey. This study 
received institutional review board exemption from the University of Texas Health Science 
Center (IRB #HSC-MS-15-0388). 
Assessment Tools 
 
The study questionnaire was comprised of different sections to assess disease history, 
treatment history, HRQoL, and demographics. The questionnaire consisted of mostly forced 
choice options with some open-ended questions. None of the items were deemed mandatory in 
the questionnaire. The survey was structured with gateway questions so that only applicable 
questions would be presented to the participant based on their answers to previous questions. The 
portion of the survey measuring HRQoL was executed using the validated tool Short Form-36 
Version 2® (SF-36v2®) Health Survey from OPTUM QualityMetric, Inc. [Jenkinson et al, 1999]. 
The SF-36v2® Health Survey questionnaire consists of 36 items forming eight scales measuring 
physical functioning, role physical, bodily pain, general health, vitality, social functioning, role 
emotion, and mental health. Scores from each of these eight scales compose total physical 
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component scores (PCS) and total mental component scores (MCS) ranging from 0 - 100 using 
QualityMetric Health Outcomes™ Scoring Software 4.5. A score of 50 indicates an average 
HRQoL score and higher scores on these scales indicate higher HRQoL. Age and gender 
matched norm data from the general United States population in 2009 was used for data 
comparison [Maruish, 2011]. Individuals currently using SRT that used ERT in the past were 
also asked questions about how their satisfaction with different aspects of their life compares 
between now and when they were using ERT as their primary treatment for type 1 GD.  
Statistical Analyses 
 
Participant responses to the survey were recorded and forced-choice question answers 
were entered into STATA
®
, a statistical software program for data analysis (v. 13. StataCorp LP, 
College Station, TX). Frequencies (with percentages) were calculated for all data. SF-36v2® PCS 
and MCS for adults using SRT were compared to United States 2009 population norms using a 
Wilcoxon signed rank test. PCS and MCS for ERT and SRT treatment groups were compared 
and analyzed using a Mann-Whitney test. Kruskal-Wallis, Chi-square, and Spearman correlation 
tests were performed to assess potential influence of demographic data including sex, age, 
income, education, and marital status on PCS and MCS. Spearman correlation tests were also 
used to determine if number of symptoms related to type 1 GD or number of other chronic 
conditions apart from type 1 Gaucher disease statistically influenced the PCS or MCS of 
participants. Descriptive statistics were used to analyze all other parts of the questionnaire. 
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RESULTS 
Description of Sample 
 
Forty-seven adults with type 1 GD completed the study questionnaire. Our study 
population consisted of 35 (74%) women, 46 (98%) Caucasians, and 29 (62%) individuals of 
Ashkenazi Jewish ancestry. Almost all participants (n=41, 87%) lived in the United States at the 
time that the survey was administered. Other participants (n=6) reported Canadian or Northern 
European residence. Participant current ages ranged from 18 to 78 years old with approximately 
one-third of participants falling in each of the following age ranges: 18-40 years, 41-60 years, 
and 60-78 years. Most participants who responded to additional demographic questions had 
achieved at least an undergraduate degree (n=34, 72%), were married (n=23, 49%), and had an 
average total annual household income less than 100,000 dollars per year (n=23, 51%) (Table 1). 
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Table 1 - Demographic and Background Characteristics of 47 Participants with Type 1 GD 
 
Characteristic 
 
n 
 
% 
Mean Age (Range) 
    18-40 
    41-60 
    61-78 
    Chose not to answer 
  
Sex 
    Female 
    Male 
  
Ethnicity 
    Caucasian 
    Hispanic/Latino 
  
Jewish ancestry 
    Yes 
    No 
  
Country of residence 
    United States 
    Other 
  
Highest level of education 
    Some college or less 
    College degree or higher 
  
Marital status 
    Married 
    Single, Divorced, or Widowed 
  
Total annual household income 
    Less than $100,000 
    $100,000 or greater 
    Chose not to answer 
49 (18 – 78) 
15 
18 
13 
  1 
  
  
35 
12 
  
  
46 
  1 
  
  
29 
18 
  
  
41 
  6 
  
  
13 
34 
  
  
23 
24 
  
  
23 
22 
  2 
  
33 
39 
28 
 
  
  
74 
26 
  
  
98 
2 
  
  
62 
38 
  
  
87 
13 
  
  
28 
72 
  
  
49 
51 
  
  
51 
49 
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Medical and Treatment History 
 
The median age that participants were diagnosed with type 1 GD was 23 years with an 
interquartile range (IQR) of 5 to 39 years of age and responses ranging from 1 to 59 years of age. 
Slightly less than two-thirds of participants (n=29, 61%) had one or more chronic conditions in 
addition to type 1 GD, the most common being hypertension (n=14), back problems (n=12), and 
arthritis (n=12) (Figure 1a).  Most participants (n=38) had one or more current symptom of type 
1 GD at the time of the survey, the most frequent being fatigue (n=30), enlarged liver (n=15), 
and enlarged spleen (n=14) (Figure 1b). 
All but one survey participant was receiving some type of therapy as a treatment for type 
1 GD at the time of this study (Table 2). The median age that individuals began treatment for 
type 1 GD was 38 years of age with an IQR of 21 to 50 years old and responses ranging from 
one to 62 years of age. Thirty-two of the 47 participants (68%) reported currently using ERT via 
intravenous infusions (Table 2). Twenty-seven of 32 ERT users reported using ERT for more 
than five years (84%) and none of these participants had been using ERT for less than one year. 
Twenty-four of the 32 ERT users (72%) reported being offered SRT by a physician in the past. 
Fourteen of the 47 total participants (30%) reported currently using SRT (Table 2). Fifty-
seven percent of these SRT users (n=8) had been using SRT for less than one year, while the 
other six had been using SRT for more than one year. Though SRT is only recently clinically 
available, one participant started SRT as an investigational therapy prior to this therapy and, as 
such, had been using SRT for more than five years. Additionally, all but one SRT user (n=13, 
93%) had used ERT in the past. Twelve of these 13 current SRT users (92%) had used ERT for 
more than one year before changing treatment methods to SRT. 
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Figure 1 - Medical History Information of Survey Participants 
 
(a)      
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - (a) Frequency chart for different number of symptoms of type 1 GD that were 
reported by survey participants (b) Frequency chart for different number of chronic conditions 
reported besides type 1 Gaucher disease by participants 
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Table 2 - Current Treatment Method and Length of Therapy Use 
 
Current Treatment Method n % 
 ERT 
     
    Less than 1 year                   
    Between 1 and 5 years 
    More than 5 years 
    Did not indicate length of therapy 
  
SRT 
     
    Less than 1 year 
    Between 1 and 5 years 
    More than 5 years 
  
No current treatment 
 32 
   
  0 
  4 
27 
  1 
  
14 
  
  8 
  5 
  1 
  
  1 
68 
  
  0 
13 
84 
  3 
  
30 
 
57 
36 
  7 
  
  2 
 
Reactions Toward SRT 
 
Individuals currently using ERT that had been offered SRT in the past by a physician 
(n=24) were asked what reasons contributed to their decision not to use SRT (Table 3). Free 
responses to this question were parsed and categorized into four themes including potential or 
experienced side effects of SRT (n=13), satisfaction with ERT (n=8), feeling as though there is 
not enough research on SRT (n=6), and not having time to do candidate testing for SRT (n=1). 
Due to the open-ended nature of the response, at times, more than one theme was applicable to 
an individual participant. 
Thirteen individuals currently using SRT were asked what reasons contributed to their 
decision to use SRT (Table 4). Free responses to this question were categorized into five themes: 
convenience of SRT (n=7), less invasive than ERT (n=4), reaction to ERT (n=2), continued SRT 
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after FDA study (n=1), and recommended by a doctor (n=1). Similar to the other open-ended 
item, more than one theme was occasionally applicable to an individual. 
Table 3 - Reasons Cited for Declining SRT 
Reason Cited Frequency Selected quotes from participants 
Side effects of SRT 
  
Satisfaction with ERT 
  
  
  
  
  
  
 
Not enough research on SRT 
  
  
  
Have not had SRT candidate 
testing 
 13 
  
8 
  
  
  
  
  
  
 
6 
  
  
  
1 
 “The possibility of [side effects]…” 
  
“My physician offered [SRT] as 
something to think about, but I chose 
not to consider it because ERT works 
so well for me.” 
  
“I prefer to have an infusion [every] 
14 days than taking tablets every day.” 
  
“I feel like [SRT] is being pushed on 
us, which makes me uneasy…. The 
drug is too new….” 
  
“[I] have not had time to do extra 
[metabolizer status] tests.” 
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Table 4 - Reasons Cited for Using SRT 
Reason Cited Frequency Selected quotes from participants 
Convenience 
  
  
  
Less invasive/Hate needles 
  
  
 Reaction to ERT 
  
  
  
 Continued after FDA studies 
  
  
  
Doctor recommended 
 7 
  
  
  
4 
  
  
2 
  
  
  
 2 
  
  
  
1 
 “It is very convenient to take [SRT] 
because I can take pills instead of 
driving to a facility to take [ERT].” 
  
“Less invasive than ERT; less 
interference with lifestyle.” 
  
 “[I] developed a serious allergic 
reaction to [ERT] after many years on 
it without any problems.” 
  
“I joined an SRT drug study during the 
ERT shortage and stayed on SRT after 
FDA approval.” 
  
“My doctor recommended [SRT].” 
 
HRQoL in ERT and SRT Current Users 
When compared to median PCS and MCS for normative 2009 SF-36v2® Health Survey 
data concerning United States adults which are 53.07 and 52.94, respectively, median PCS and 
MCS for current SRT users were slightly lower (p < 0.001 and p = 0.014). The median PCS 
resulting from the SF-36v2® Health Survey for the 32 current ERT users was 48.16 (IQR of 
41.48 to 53.66), while the median PCS was 49.29 (IQR of 39.37 to 55.53) for the 14 current SRT 
users (Figure 2a). No statistically significant difference in PCS was observed between current 
ERT and current SRT users (p = 0.756). The median MCS for current ERT and current SRT 
users were 50.68 (IQR of 43.76 to 55.76) and 50.08 (IQR of 42.93 to 54.67), respectively (Figure 
13 
2b). Similarly, no significant difference in MCS was discerned between these two treatment 
groups (p = 0.650).  
When PCS and MCS for all users were stratified by sex, income, education, marital status 
and number of other chronic conditions excluding type 1 GD, no statistically significant 
influence on PCS and MCS for HRQoL was observed. The number of symptoms related to type 
1 GD that a participant experienced was statistically associated with a negative influence on PCS 
(p < 0.001) and MCS (p < 0.001). Furthermore, while no association of age and PCS was 
observed (p = 0.103), there was a correlation observed concerning increased age and increased 
MCS (p = 0.003). 
Perceived Changes in HRQoL in SRT Sample 
 
Twelve current SRT users who reported using ERT in the past responded to items 
comparing their perceptions of health for both treatments with regard to five health categories: 
“general health”, ability to complete everyday activities or “physical ability”, “emotional health”, 
“social interactions”, and “satisfaction with life”. More than half (n=7) of the current SRT users 
report no difference in their perception of health while using SRT as compared to ERT with 
regard to general health, emotional health, social interactions, and satisfaction with life. Two-
thirds (n=8) of current SRT users report no perception of difference in health between therapy 
options with regard to physical ability (Figure 3). Between one and two current SRT users per 
health category reported having a somewhat better or much better perception of health while 
using SRT as compared to when using ERT. Two participants reported experiencing much worse 
health while using SRT than when using ERT for each of these five health categories. These two 
participants both indicated in free response items that their only reasons for using SRT were that 
they “hate needles” and that they experienced side effects of SRT. 
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Figure 2 - Physical and Mental HRQoL Component Scores by Therapy 
 
 
(a)     
   
 
 
 
 
 
 
 
 
 
 
 
 
 
(b)  
             
 
 
 
Figure 2 - (a) Boxplot of SF-36v2
®
 Health Survey PCS of current ERT and SRT users by 
therapy (b) Boxplot of SF-36v2
®
 Health Survey MCS of current ERT and SRT users by therapy  
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Figure 3 - Perceived Changes in HRQoL in SRT Users who Used ERT in Past 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 - Stacked column chart of SRT users’ perceptions of current health as compared to 
health during past use of ERT 
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DISCUSSION 
 
GD is the most common inherited LSD, affecting approximately 1 in every 60,000 to 
100,000 people worldwide [Meikle et al, 1999; Poorthuis et al, 1999]. Treatment for type 1 
Gaucher disease has traditionally been administered in the form of ERT via biweekly 
intravenous infusions. However, in August, 2014, an oral SRT was approved by the FDA for 
clinical treatment of type 1 GD. While evidence in the literature suggests that the use of ERT 
improves HRQoL for individuals with type 1 GD, no study to date has investigated the HRQoL 
of those using SRT as a therapy for type 1 GD [Damiano et al, 1998; Masek et al, 1999; Weinreb 
et al, 2007]. 
The most common reasons current ERT users declined the use of SRT were potential or 
experienced side effects and satisfaction with ERT. Previous research of therapy preferences in 
chronic inherited conditions, such as hemophilia, have shown that risk of side effects are a major 
factor in patient preferences for a particular therapy [Scalone et al, 2009; Mohamed et al, 2011; 
Chaugule et al, 2015]. This study shows that the risk of side effects as a marker for therapy 
preference extends to patients with type 1 GD that considered the switch from ERT to SRT. The 
idea that individuals who were satisfied with their use of ERT and, perhaps, were comfortable 
with the routine of their bi-weekly intravenous infusions was not a surprising one, especially 
considering that greater than 84% of current ERT users had been using ERT for more than five 
years. However, it was unexpected that two current ERT users perceived having an intravenous 
infusion of ERT every 14 days as more convenient than taking oral tablets as treatment for type 1 
GD. These results are possibly a reflection of patients’ preferences for course of treatment. If so, 
this may be reminiscent of the resistance to new therapies in the context of other medical 
conditions.  An investigation of patient preferences for treatment of chronic hematological 
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conditions showed that even if new treatments become available, a large percentage of patients 
feel uncertain about or refuse change in treatment [Renzi et al, 2015]. Additionally, research 
regarding patients with β-thalassemia found that this population may be resistant to switching 
from intravenous infusions to oral therapies, perhaps due to conflicted feelings of trying a new 
therapy when they are satisfied with a current treatment method [Trachtenberg et al, 2014].  
The most common reasons current SRT users cited as contributing to their decision to use 
this therapy were convenience and the less invasive nature of SRT. Due to the difference in the 
route of administration for ERT and SRT, convenience and less invasiveness were predicted 
advantages that current SRT users would cite as reasons for using this new therapy for type 1 
GD. Other SRT users mentioned continuing SRT after the FDA clinical trial because this therapy 
was effective or that their doctor recommended this type of therapy. These findings mirror 
reasons why other patient populations, including those with multiple sclerosis, have switched 
therapies in the past. A study of individuals receiving treatment for multiple sclerosis in 2014 
revealed that the main reasons cited for switching therapies was because a doctor recommended 
the new treatment or because the patient perceived it as an effective treatment option [Salter et 
al, 2014]. 
Median PCS and MCS for individuals using SRT to treat type 1 GD were slightly lower 
than median PCS and MCS for United States adults who took the SF-36v2® Health Survey in 
2009. Previous studies revealed that individuals with type 1 GD have lower HRQoL than 
average and that people with type 1 GD using ERT have increased HRQoL as compared to those 
not receiving treatment [Damiano et al, 1998; Masek et al, 1999; Weinreb et al, 2007]. While we 
did not specifically compare the HRQoL of current SRT users to those with the type 1 GD that 
are not receiving treatment, it is possible that current SRT users may have decreased HRQoL as 
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compared to adults without type 1 GD since these individuals still experience a rare and chronic 
medical condition that necessitates treatment.  
No significant difference in PCS or MCS between current ERT and SRT users was 
observed. The use of SRT was hypothesized to increase HRQoL above that of individuals using 
ERT to treat type 1 GD since it is considered by many to be a more convenient and less invasive 
type of therapy. This hypothesis was not confirmed by this data; however, our findings are 
substantial in the investigation of SRT as a newly approved therapy for type 1 GD. This is due to 
the demonstration that SRT is, on average, just as effective at maintaining HRQoL in individuals 
with type 1 GD as ERT. Moreover, current SRT users that used ERT in the past most often 
reported no difference in their perception of different aspects of health when asked to compare 
their current health to their health while using ERT. Although self-perceptions of health are 
subjective to the individual, it was unexpected that the majority of current SRT users would 
perceive no difference in these categories related to HRQoL with respect to the two treatment 
options. Of note, two of the 12 respondents for this set of items indicated that each of the five 
aspects of their health inquired about were “much worse now with SRT” than when they used 
ERT in the past. These two participants also commented that they experienced side effects 
related to SRT. While the convenience of SRT may be an attractive component of this treatment 
method, if individuals with type 1 GD experience side effects related to their therapy, this may 
not be the ideal treatment regimen for these patients.  
The study offers considerable strengths relevant to the interpretation of these findings. Of 
great importance is that this is the first study to address the potential influence of SRT for type 1 
GD on HRQoL, rather than the purely physiological parameters of other research regarding this 
novel treatment option. This report is also the first to address participants’ perceptions of why 
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individuals have chosen or declined the use of SRT for type 1 GD in comparison to the 
traditional intravenous infusion of ERT. Additionally, this study was administered electronically 
and, therefore, had participants from across the United States and other countries. This part of 
our study design was intentional in order to eliminate the potential sample bias of patients with 
type 1 GD at a single treatment center. 
Despite these strengths, there are also some limitations with regard to the results of this 
study. The number of participants that were current SRT users is small and greater numbers of 
current SRT users with type 1 GD would be desired to corroborate these findings in a bigger 
sample. While a large sample size is ideal, type 1 GD is a rare disease and, since SRT has only 
been clinically available outside of FDA drug trials since August 2014, there are few members of 
the GD community currently using SRT. Because SRT is only available to adult patients, there is 
the possibility for a larger population to better assess the effects of SRT on HRQoL in the future 
as younger patients with type 1 GD become adults and potentially elect SRT. Another potential 
bias for this study is that many of the participants were recruited from GD electronic support 
forums and the National Gaucher Foundation membership. Selecting study participants from 
electronic information and support communities may introduce a sample bias if the responses of 
these participants are not comparable to that of the average adult with type 1 GD [Gawlinski et 
al, 2009]. Our group corrected for this possible bias by extending invitations to participate to 
patients of medical geneticists and metabolic genetic counselors that have type 1 GD. Despite 
this, participants were not asked to report how they learned about this study so a reliable 
response rate from different participant sources cannot be calculated. Lastly, our sample had a 
large proportion of participants that were Caucasian, well educated, and financially successful. 
While this may be representative of the type 1 GD population in general as compared to the 
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average adult in the United States, this sample makeup could also potentially introduce influence 
on the results of this study. 
Another important aspect of this study’s analysis is that the SF-36v2® Health Survey was 
administered at only one point in time to each participant. Therefore, while current SRT users 
were asked to compare various aspects of their self-perceived health as compared to when using 
ERT, a more precise comparison regarding the effect of SRT on HRQoL may be obtained in a 
study that collects HRQoL scores at various points in time for ERT users with type 1 GD that 
switch to SRT. This proposed methodology would allow for matched statistical comparison for 
individuals that have used both therapies and also allow for HRQoL comparison depending on 
how long participants have used a certain therapy for type 1 GD. Finally, there is no way to 
account for all of the factors that may influence someone’s HRQoL. Analysis of sex, income, 
education, marital status, and number of chronic conditions other than type 1 GD showed no 
statistically significant association with or influence on HRQoL scores for current ERT or 
current SRT users. Unsurprisingly, the higher number of symptoms someone experienced as 
related to type 1 GD was associated with a lower PCS and MCS. Increase in age also showed a 
slight association with increase in MCS within our sample. This is not a typical observation in 
the general population but is one that has been seen in individuals with some chronic mental 
health disorders [Folsom et al, 2009].  Despite these findings, the small sample size limited the 
use of larger multivariable analytic models adjusting for various factors. Furthermore, it is 
possible that a factor not accounted for in this survey could influence the PCS and MCS and, 
therefore, the HRQoL of all participants. 
Overall, the results of this study propose that there is no significant difference in HRQoL 
between current ERT and current SRT users for type 1 GD. This is in addition to previous 
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literature showing that the efficacy of SRT to treat physical symptoms of type 1 GD is 
comparable to traditional ERT [Kamath et al, 2014; Lukina et al, 2014; Poole, 2014; Mistry et al, 
2015]. Based on this evidence, the effects of SRT on the individual appear to be similar to those 
of ERT unless patients experience side effects related to therapy that could reduce HRQoL. 
Furthermore, many patients that use either ERT or SRT cite a variety of reasons, many of which 
are individualized, for why they may prefer their current treatment to another option. Together, 
these findings suggest that individuals with type 1 GD should be thoroughly counseled about the 
risks and benefits of both forms of therapy when beginning treatment or establishing care for this 
condition.  
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